NBE-Therapeutics
Biotech company (Basel, Switzerland) focused on antibody-drug conjugate (ADC) R&D. Develops site-specific conjugation methods, anthracycline-based ADC payloads, and mammalian cell-based antibody discovery to generate homogeneous ADCs with immuno-oncology activity. Wholly owned subsidiary of Boehringer Ingelheim since 2020.
Industries
Nr. of Employees
small (1-50)
NBE-Therapeutics
Patents
Anthracycline-based antibody drug conjugates having high in vivo tolerability
US-12121527-B2
View Details
Anthracycline-based antibody drug conjugates having high in vivo tolerability
US-12121527-B2
View DetailsProducts
Antibody-drug conjugate development platform
Integrated platform combining antibody discovery, site-specific conjugation and anthracycline-based payloads to generate homogeneous ADCs with defined DAR and documented immuno-oncology activity in preclinical models.
PNU Anthracycline Payload
Highly potent anthracycline-based DNA damaging intercalating toxin with pico molar potency.
SMAC
NBE-Therapeutics proprietary sortase-enzyme mediated antibody conjugation technology to generate homogenous ADCs with a highly defined and precisely adjustable Drug-to-Antibody-Ratio.
iADC
Immune-oncology antibody-drug conjugates developed by NBE-Therapeutics that induce sustained and long-lasting anti-tumor immunity and protect against tumor re-challenge.
Antibody Discovery
Platform for discovering novel binders against any novel target using a mammalian antibody library display system.
Transpo-mAb Display
A novel antibody discovery method involving mammalian cell display based on the expression of libraries of full-length antibodies on the surface of precursor B cells mediated by stable DNA-Transposition.
Antibody-drug conjugate development platform
Integrated platform combining antibody discovery, site-specific conjugation and anthracycline-based payloads to generate homogeneous ADCs with defined DAR and documented immuno-oncology activity in preclinical models.
PNU Anthracycline Payload
Highly potent anthracycline-based DNA damaging intercalating toxin with pico molar potency.
SMAC
NBE-Therapeutics proprietary sortase-enzyme mediated antibody conjugation technology to generate homogenous ADCs with a highly defined and precisely adjustable Drug-to-Antibody-Ratio.
iADC
Immune-oncology antibody-drug conjugates developed by NBE-Therapeutics that induce sustained and long-lasting anti-tumor immunity and protect against tumor re-challenge.
Antibody Discovery
Platform for discovering novel binders against any novel target using a mammalian antibody library display system.
Transpo-mAb Display
A novel antibody discovery method involving mammalian cell display based on the expression of libraries of full-length antibodies on the surface of precursor B cells mediated by stable DNA-Transposition.
Services
Partnering on ADC discovery and early-stage development activities, including antibody discovery, payload selection, conjugation development and preclinical evaluation.
Partnering on ADC discovery and early-stage development activities, including antibody discovery, payload selection, conjugation development and preclinical evaluation.
Expertise Areas
- Antibody-drug conjugate development
- Antibody discovery and engineering
- Payload chemistry for ADCs
- Site-specific conjugation and DAR optimization
Key Technologies
- Site-specific enzymatic conjugation (sortase A)
- Anthracycline-derived ADC payloads (PNU-159682)
- Mammalian cell display (transposition-mediated B-cell display)
- Functional screening of full-length IgG libraries
News & Updates
New R&D center opened in Basel to support ADC research and development as part of parent company’s oncology strategy.
Announcement of appointment of Olof Prause as COO responsible for operational strategy and execution, effective 01 September 2025.
Publication describing enzymatic generation of site-specifically conjugated ADCs using sortase-mediated coupling with in vitro and in vivo potency data.
Publication on highly potent anthracycline-based ADCs generated by enzymatic, site-specific conjugation.
Study reporting that an anthracycline-based ADC induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer models.
Study characterizing heterogeneous ROR1 protein expression across tumor types.
New R&D center opened in Basel to support ADC research and development as part of parent company’s oncology strategy.
Announcement of appointment of Olof Prause as COO responsible for operational strategy and execution, effective 01 September 2025.
Publication describing enzymatic generation of site-specifically conjugated ADCs using sortase-mediated coupling with in vitro and in vivo potency data.
Publication on highly potent anthracycline-based ADCs generated by enzymatic, site-specific conjugation.
Study reporting that an anthracycline-based ADC induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer models.
Study characterizing heterogeneous ROR1 protein expression across tumor types.